Annual infusion of zoledronic acid reduces days of back pain, disability, and bed rest .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292In a secondary prespecified analysis, 7736 postmenopausal women with osteoporosis were examined to evaluate the effect of once-yearly zoledronic acid on improving back pain and disability. Patients received either a single 15 minute intravenous fusion of zoledronic acid (5 mg) or placebo at baseline, 12 months, and 24 months. The assessment at 36 months indicated that zoledronic acid significantly reduced the number of days with back pain when compared to placebo. Additionally, zoledronic acid reduced the number of days of limited activity due to back pain and limited activity and bed rest after a fracture.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
